Obesity: What you need to know about the arrival of the tablet version of the Wegovy treatment

It has been the subject of many opinions, sometimes contradictory. Wegovy, a treatment against obesity developed by the Danish laboratory Novo Nordisk, will be available in pharmacies in the form of tablets in France from November 2, announces Le Parisien. This medication is one of the GLP-1 analogs, a class of medications that controls blood sugar and helps you lose weight by acting as an appetite suppressant. This treatment was already offered in the form of an injection only by prescription. For patients with massive obesity, 65% of the treatment was covered by Health Insurance.

Which will not be the case for tablets. A notable difference. Because according to the general manager of Novo Nordisk France, the swallowable treatment will be offered at a price of 169 euros for one month of treatment. “A price similar to injectable treatment,” Étienne Tichit told Parisian.

According to the laboratory, around 100,000 patients are treated at Wegovy in France. Around “30% of them would prefer to take tablets rather than having to give injections every week,” assure our colleagues at RTL. The Danish pharmaceutical group, however, has not filed a file with the High Authority for Health to obtain reimbursement.

Alerts due to misuse